PDCD1 and neoplasm: The efficacy of immune checkpoint inhibitors (ICIs) varied with tumor types, but it is generally believed that high PD-L1 expression level is associated with favorable clinical outcomes to anti PD-1/anti PD-L1 therapy (Table 1).